Unión Europea - español - EMA (European Medicines Agency)

pfizer europe ma eeig - etanercept - arthritis, psoriatic; spondylitis, ankylosing; psoriasis - inmunosupresores - la artritis reumatoide;idiopática juvenil arthritispsoriatic artritis;axial spondyloarthritis;la placa de psoriasis;pediátrica de la placa de psoriasis.

Unión Europea - español - EMA (European Medicines Agency)

tesaro bio netherlands b.v. - rolapitant - vomiting; nausea; cancer - los antieméticos y antinauseants, - prevención de náuseas y vómitos retardados asociados con la quimioterapia contra el cáncer altamente emetógena moderada en adultos. varuby se administra como parte de la terapia de combinación.

Unión Europea - español - EMA (European Medicines Agency)

abbvie deutschland gmbh co. kg - ombitasvir, paritaprevir, ritonavir - hepatitis c, crónica - antivirales para uso sistémico - viekirax está indicado en combinación con otros medicamentos para el tratamiento de la hepatitis c crónica (chc) en adultos. para el virus de la hepatitis c (vhc) de genotipo específico de la actividad.

Unión Europea - español - EMA (European Medicines Agency)

abbvie ltd - dasabuvir sódico - hepatitis c, crónica - antivirales para uso sistémico - exviera está indicado en combinación con otros medicamentos para el tratamiento de la hepatitis c crónica (chc) en adultos. para el virus de la hepatitis c (vhc) de genotipo específico de la actividad.

Unión Europea - español - EMA (European Medicines Agency)

eco animal health europe limited - tylvalosin - antiinfectives para uso sistémico, antibacterianos para uso sistémico, macrólidos - pheasants; chicken; turkeys; pigs - pigstreatment y methaphylaxis de la neumonía enzoótica porcina;tratamiento de la enteropatía proliferativa porcina (ileitis);el tratamiento y methaphylaxis de la disentería porcina. chickenstreatment y methaphylaxis de enfermedad respiratoria asociada con mycoplasma gallisepticum en pollos. pheasantstreatment de enfermedad respiratoria asociada con mycoplasma gallisepticum. turkeystreatment de enfermedad respiratoria asociada con la tilvalosina cepas sensibles de ornithobacterium rhinotracheale en pavos.

Unión Europea - español - EMA (European Medicines Agency)

nova laboratories ireland limited - azathioprine - rechazo del injerto - inmunosupresores - jayempi is indicated in combination with other immunosuppressive agents for the prophylaxis of transplant rejection in patients receiving allogenic kidney, liver, heart, lung or pancreas transplants. azathioprine is indicated in immunosuppressive regimens as an adjunct to immunosuppressive agents that form the mainstay of treatment (basis immunosuppression). jayempi is used as an immunosuppressant antimetabolite either alone or, more commonly, in combination with other agents (usually corticosteroids) and/ or procedures which influence the immune response. jayempi is indicated in patients who are intolerant to glucocorticosteroids or if the therapeutic response is inadequate despite treatment with high doses of glucocorticosteroids, in the following diseases:severe active rheumatoid arthritis (chronic polyarthritis) that cannot be kept under control by less toxic agents (disease-modifying anti-rheumatic -medicinal products – dmards)auto-immune hepatitis systemic lupus erythematosusdermatomyositispolyarteritis nodosapemphigus vulgaris and bullous pemphigoidbehçet’s diseaserefractory auto-immune haemolytic anaemia, caused by warm igg antibodieschronic refractory idiopathic thrombocytopenic purpurajayempi is used for the treatment of moderately severe to severe forms of chronic inflammatory bowel disease (ibd) (crohn’s disease or ulcerative colitis) in patients in whom glucocorticosteroid therapy is necessary, but where glucocorticosteroids are not tolerated, or in whom the disease is untreatable with other common means of first choice. it is also indicated in adult patients in relapsing multiple sclerosis, if an immunomodulatory therapy is indicated but beta interferon therapy is not possible, or a stable course has been achieved with previous treatment with azathioprine. 3jayempi is indicated for the treatment of generalised myasthenia gravis. depending on the severity of the disease, jayempi should be given in combination with glucocorticosteroids because of slow onset of action at the beginning of treatment and the glucocorticosteroid dose should be gradually reduced after several months of treatment.

Perú - español - DIGEMID (Dirección General de Medicamentos, Insumos y Drogas)

fresenius medical care del peru s.a. -

Unión Europea - español - EMA (European Medicines Agency)

nova laboratories ireland limited - monohidrato de 6-mercaptopurina - leucemia, linfoide - agentes antineoplásicos - xaluprine está indicado para el tratamiento de la leucemia linfoblástica aguda (lla) en adultos, adolescentes y niños.

Chile - español - ISPC (Instituto de Salud Pública de Chile)

oriflame de chile s.a. - sin formulas

Chile - español - ISPC (Instituto de Salud Pública de Chile)

oriflame de chile s.a. - sin formulas